Dabigatran performs well in study

01/3/2013 | Healio

The anticoagulant dabigatran performed safely and effectively in a group of 938 unselected patients with atrial fibrillation, according to a German study presented at a meeting. Less than 2% of the patients experienced major cardiovascular events, and 1% experienced minor cardiovascular events. Bleeding complications were experienced by 14.9% of patients, but only 1.5% faced major bleeding, the study found.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA